FDA Approves Tryngolza for Rare Cholesterol Disease.

The article reports the U.S. Food and Drug Administration's (FDA) approval of Tryngolza (olezarsen), a monthly subcutaneous ribonucleic acid (RNA)-targeted therapy by Ionis Pharmaceuticals for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). Topics include its mechanism targeting apolipoprotein C-III, significant reductions in triglycerides and pancreatitis in clinical trials, and its 595,000 U.S. Dollar price, with financial support programs for patients.